bioRxivImmunology
Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses
S. Xu, O. Chaudhary, P. Rodriguez-Morales, X. Sun, R. Zappasodi, Z. Xu, A. F. M. Pinto, A. Williams, D. Chen, J. S. Low, Y. Farsakoglu, W. Tang, H. Wang, S. K. Varanasi, B. McDonald, V. Tripple, M. Downes, R. M. Evans, N. A. Abumrad, T. Merghoub, J. D. Wolchok, M. N. Shokhirev, P.-C. Ho, J. L. Witztum, B. Emu, , S. M. Kaech
Abstract
T cell metabolic fitness plays a pivotal role in anti-tumor immunity and metabolic deregulation causes T cell dysfunction (i.e., exhaustion) in cancer. We identify that the scavenger receptor CD36 limits anti-tumor CD8+ T cell effector functions through lipid peroxidation. In murine tumors, oxidized phospholipids (OxPLs) were highly abundant and CD8+ TILs increased uptake and accumulation of lipids and lipid peroxidation. Functionally exhausted CD8+ TILs substantially increased CD36 expression and CD36-deficient CD8+ TILs had more robust anti-tumor activity and cytokine production than wild-type cells. We further show that CD36 promotes uptake of oxidized low-density lipoproteins (OxLDL) and induces lipid peroxidation in CD8+ TILs, and OxLDL inhibits CD8+ T cell functions in a CD36-dependent manner. Moreover, glutathione peroxidase 4 (GPX4) over-expression lowers lipid peroxidation and restores functionalities in CD8+ TILs. These results define a key role for an oxidized lipid-CD36 axis in promoting intratumoral CD8+ T cell dysfunction.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lack of Bcl6 promotes anti-tumor immunity by activating glycolysis to rescue CD8 T cell function
Fangkun Luan, Yunqiao Li, … David A. Nemazee·bioRxiv·Apr 1, 2025
- Inducing an oxidized redox-balance improves anti-tumor CD8+ T cell function
J. H. Oh, R. A. Cederberg, … R. I. K. Geltink·bioRxiv·Mar 27, 2023
- Pharmacologic DPP-4 inhibition promotes CD8⁺ T cell metabolic fitness to enhance anti-tumor activity
Oriana Teran Pumar, Elton L VanNoy, … Defne Bayık·bioRxiv·Apr 3, 2026
- TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity
Matthew P. Jackson, T. Zhao, … Eileen E. Parkes·bioRxiv·Jan 2, 2026
- Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
O.-Y. Revach, A. M. Cicerchia, … K. Yizhak·bioRxiv·Feb 12, 2024
- Resilient CD8+ T cells maintain a high cytotoxic capacity by balancing ROS via ME1 upregulation
J. K. Gicobi, Z. Mao, … H. Dong·bioRxiv·Nov 25, 2022